BACKGROUND: There is controversy regarding the optimal management of thyroid cancer. The proportion of patients with low-risk thyroid cancer who received radioactive iodine (RAI) treatment increased over the last 20 years, and little is known about the role played by clinicians in hospital-level RAI use for low-risk disease. METHODS: Thyroid surgeons affiliated with 368 hospitals that had Commission on Cancer-accredited cancer programs were surveyed. Survey data were linked to data reported to the National Cancer Database. A multivariable analysis was used to assess the relation between clinician decision makers and hospital-level RAI use after total thyroidectomy in patients with stage I, well differentiated thyroid cancer. RESULTS: The survey response rate was 70% (560 of 804 surgeons). The surgeon was identified as the primary decision maker by 16% of the surgeons; the endocrinologist was identified as the primary decision maker by 69%, and a nuclear medicine, radiologist, or other physician was identified as the primary decision maker by 15%. In a multivariable analysis controlling for hospital case volume and hospital type, when the primary decision maker was in a specialty other than endocrinology or surgery, there was greater use of RAI at the hospital (P < .001). A greater number of providers at the hospital where RAI was administered and having access to a tumor board also were associated with increased use of RAI (P < .001 and P = .006, respectively). CONCLUSIONS: The specialty of the primary decision maker, the number of providers administering RAI, and having access to a tumor board were associated significantly with the use of RAI for stage I thyroid cancer. The findings have implications for addressing nonclinical variation between hospitals, with a marked heterogeneity in decision making suggesting that standardization of care will be challenging.
BACKGROUND: There is controversy regarding the optimal management of thyroid cancer. The proportion of patients with low-risk thyroid cancer who received radioactive iodine (RAI) treatment increased over the last 20 years, and little is known about the role played by clinicians in hospital-level RAI use for low-risk disease. METHODS: Thyroid surgeons affiliated with 368 hospitals that had Commission on Cancer-accredited cancer programs were surveyed. Survey data were linked to data reported to the National Cancer Database. A multivariable analysis was used to assess the relation between clinician decision makers and hospital-level RAI use after total thyroidectomy in patients with stage I, well differentiated thyroid cancer. RESULTS: The survey response rate was 70% (560 of 804 surgeons). The surgeon was identified as the primary decision maker by 16% of the surgeons; the endocrinologist was identified as the primary decision maker by 69%, and a nuclear medicine, radiologist, or other physician was identified as the primary decision maker by 15%. In a multivariable analysis controlling for hospital case volume and hospital type, when the primary decision maker was in a specialty other than endocrinology or surgery, there was greater use of RAI at the hospital (P < .001). A greater number of providers at the hospital where RAI was administered and having access to a tumor board also were associated with increased use of RAI (P < .001 and P = .006, respectively). CONCLUSIONS: The specialty of the primary decision maker, the number of providers administering RAI, and having access to a tumor board were associated significantly with the use of RAI for stage I thyroid cancer. The findings have implications for addressing nonclinical variation between hospitals, with a marked heterogeneity in decision making suggesting that standardization of care will be challenging.
Authors: Steven J Katz; Sarah T Hawley; Paul Abrahamse; Monica Morrow; Christopher R Friese; Amy K Alderman; Jennifer J Griggs; Ann S Hamilton; John J Graff; Timothy P Hofer Journal: Med Care Date: 2010-10 Impact factor: 2.983
Authors: Brahmajee K Nallamothu; Mary A M Rogers; Michael E Chernew; Harlan M Krumholz; Kim A Eagle; John D Birkmeyer Journal: JAMA Date: 2007-03-07 Impact factor: 56.272
Authors: Jennifer L Marti; Louise Davies; Megan R Haymart; Benjamin R Roman; R Michael Tuttle; Luc G T Morris Journal: Thyroid Date: 2015-05-28 Impact factor: 6.568
Authors: Ryan K Orosco; Timon Hussain; Julia E Noel; David C Chang; Chrysoula Dosiou; Erik Mittra; Vasu Divi; Lisa A Orloff Journal: Endocr Relat Cancer Date: 2019-10 Impact factor: 5.678
Authors: Archana Radhakrishnan; David Reyes-Gastelum; Brittany Gay; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Lauren P Wallner; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Kathryn M Schuessler; Mousumi Banerjee; Di Yang; Andrew K Stewart; Gerard M Doherty; Megan R Haymart Journal: Ann Surg Oncol Date: 2012-12-06 Impact factor: 5.344
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; James C Sisson; Ronald J Koenig; Gerard M Doherty; Jennifer J Griggs Journal: J Clin Endocrinol Metab Date: 2013-03-28 Impact factor: 5.958
Authors: Mousumi Banerjee; Daniel G Muenz; Joanne T Chang; Maria Papaleontiou; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2014-07-17 Impact factor: 5.958
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Jennifer J Griggs; James C Sisson; Ronald J Koenig Journal: Endocr Pract Date: 2013 Jul-Aug Impact factor: 3.443